Celgene Reports Second Quarter 2018 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Celgene (CELG) PT Raised to $101 at SunTrust Robinson Humphrey
July 27, 2018 8:06 AM EDTSunTrust Robinson Humphrey raised its price target on Celgene (NASDAQ: CELG) to $101.00 (from $96.00) while maintaining a Hold rating.
Analyst Yatin Suneja commented, "CELG reported 2Q sales above consensus on good performances from all core products except Otezla and Abraxane, while... More
Celgene (CELG) Tops Q2 EPS by 5c, Raises FY EPS Guidance
July 26, 2018 7:34 AM EDTCelgene (NASDAQ: CELG) reported Q2 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $3.81 billion versus the consensus estimate of $3.7 billion.
GUIDANCE:
Celgene sees FY2018 EPS of $8.70-$8.75, versus the consensus of $8.52. Celgene sees... More
